Biomatrix Features Relevant to Bifurcational Stenting and the LEADERS Bifurcation Substudy
European Bifurcation Club 2010 – EBC 2010 – Budapest, Hungary
New DES and bifurcation stenting
Biomatrix Features Relevant to Bifurcational Stenting and the LEADERS Bifurcation Substudy
Author: Carlo Di Mario, Nicolas Foin, Imperial College London, UK
BIOLIMUS A9 ELUTING BIOMATRIX STENT
- Biolimus is a semi-synthetic sirolimus analogue with 10x higher lipophilicity and similar potency as sirolimus.
- Biolimus is immersed into a biodegradable polymer, polylactic acid, and applied solely to the abluminal stent surface
- Biolimus is co-released with polylactic acid that completely desolves into carbon dioxide and water after a 6-9 months period.
- The same coating and drug has been successfully used in bifurcational trials with the dedicated self- expanding DEVAX platform
- The stainless steel stent platform has a strut thickness of 120 μm with a quadrature link design.
CONCLUSION
- The Biomatrix Flex stent offers a large opening when dilated through the struts, sufficient to fit almost all coronary anatomies
- Biolimus eluting stent appears to offer an advantage in treating patients with bifurcational lesions
- Larger cohorts of prospectively collected data as well as mechanistic insights are needed to confirm these findings.